Glucagon-Like Peptide 1 Recruits Muscle Microvasculature and Improves Insulin’s Metabolic Action in the Presence of Insulin Resistance
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) acutely recruits muscle microvasculature, increases muscle delivery of insulin, and enhances muscle use of glucose, independent of its effect on insulin secretion. To examine whether GLP-1 modulates muscle microvascular and metabolic insulin responses in the setting of insulin resistance, we assessed muscle microvascular blood volume (MBV), flow velocity, and blood flow in control insulin-sensitive rats and rats made insulin-resistant acutely (systemic lipid infusion) or chronically (high-fat diet [HFD]) before and after a euglycemic-hyperinsulinemic clamp (3 mU/kg/min) with or without superimposed systemic GLP-1 infusion. Insulin significantly recruited muscle microvasculature and addition of GLP-1 further expanded muscle MBV and increased insulin-mediated glucose disposal. GLP-1 infusion potently recruited muscle microvasculature in the presence of either acute or chronic insulin resistance by increasing muscle MBV. This was associated with an increased muscle delivery of insulin and muscle interstitial oxygen saturation. Muscle insulin sensitivity was completely restored in the presence of systemic lipid infusion and significantly improved in rats fed an HFD. We conclude that GLP-1 infusion potently expands muscle microvascular surface area and improves insulin’s metabolic action in the insulin-resistant states. This may contribute to improved glycemic control seen in diabetic patients receiving incretin-based therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These include promoting muscle remodel, enhancing postprandial muscle protein synthesis, increasing muscle microvascular blood flow, and improving muscle insulin resistance through weight loss [55, 56].”
From Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis (2025) · cites this paper as [56]
In the citing paper
“Since GLP-1Rs are absent in human skeletal muscle, effects must be indirect.”
From Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis (2025) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“Glucagon-like peptide 1 (GLP-1), an incretin secreted in response to nutrient intake, stimulates glucosedependent insulin secretion, inhibits glucagon secretion and regulates postprandial glycemia (16,17).”
BackgroundYu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K., Cushman, S. W., Cooney, G. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200958200 · Cited by 1,561
Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311 · cited 1×
“5 h after systemic lipid infusion (8,33), but extension of lipid infusion to 5 h significantly increases myocytic diacylglycerol concentration and protein kinase Cu activation and reduces insulin-mediated insulin receptor substrate-1 tyrosine phosphorylation and insulin receptor substrate-1–associated PI3-kinase activ…”
BackgroundDeFronzo, R. A., Gunnarsson, R., Björkman, O., Olsson, M., & Wahren, J. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111938 · Cited by 1,167 · cited 1×
“Skeletal muscle is a major target organ of insulin action and responsible for;80–90% of insulin-stimulated whole-body glucose disposal (1,2).”
BackgroundYe, J., Gao, Z., Yin, J., & He, Q. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00435.2007 · Cited by 840 · cited 1×
“Indeed, recent studies have shown that tissue hypoxia may contribute to the pathogenesis of insulin resistance likely via increased tissue inflammation (45).”
BackgroundNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · cited 2×
“These likely resulted from a direct action of GLP-1 on the endothelium as GLP-1 receptors are abundantly expressed on the vascular endothelium (21), and studies using rat arterial rings have shown a direct, dose-dependent vasorelaxant effect of GLP-1 that was abolished by the removal of the endothelium (22).”
BackgroundThe role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 614 · cited 1×
“Glucagon-like peptide 1 (GLP-1), an incretin secreted in response to nutrient intake, stimulates glucosedependent insulin secretion, inhibits glucagon secretion and regulates postprandial glycemia (16,17).”
BackgroundCardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530 · cited 1×
“GLP-1 also has many nonpancreatic actions, including a beneficial effect on the endothelium (18).”
BackgroundNikolaidis, L. A., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias, L., Stolarski, C., Shen, Y.-T., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000139339.85840.dd · Cited by 514 · cited 3×
“To examine whether GLP-1-mediated microvascular recruitment modulates insulin’s metabolic actions, we raised plasma insulin (3 mU/kg/min euglycemic insulin clamp) for 120 min after determining baseline MAP and collecting baseline samples for glucose and insulin levels at 0 min with or without a superimposed systemic i…”
BackgroundMethodKubota, T., Kubota, N., Kumagai, H., Yamaguchi, S., Kozono, H., Takahashi, T., Inoue, M., Itoh, S., Takamoto, I., Sasako, T., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.01.018 · Cited by 435 · cited 1×
“Recent evidence has confirmed a pivotal role of muscle microvasculature in the determination of muscle insulin action, as it provides the endothelial exchange surface area and changes in muscle microvascular perfusion profoundly affect insulin delivery to and action in muscle (5,6).”
Background
Cited by
Short-chain fatty acids as potential regulators of skeletal muscle metabolism and function
Frampton, J., Murphy, K. G., Frost, G., & Chambers, E. S. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0188-7 · Cited by 516
van Deuren, T., Blaak, E. E., & Canfora, E. E. (2022) · Obesity Reviews · doi:10.1111/obr.13498 · Cited by 181
Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Boer, G. A., & Holst, J. J. (2020) · Biology · doi:10.3390/biology9120473 · Cited by 155
Horiuchi, H., Kamikado, K., Aoki, R., Suganuma, N., Nishijima, T., Nakatani, A., & Kimura, I. (2020) · Scientific Reports · doi:10.1038/s41598-020-60984-6 · Cited by 115
Glucagon-like peptide-1 receptor action in the vasculature
Almutairi, M., Al Batran, R., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2018.09.002 · Cited by 99
Metadata
- Authors
- Chai, W., Zhang, X., Barrett, E. J., & Liu, Z.
- Affiliations
- University of Virginia Health System (US)
- Central South University (CN)
- Corresponding author
- Liu, Zhenqi
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-07-17
- Volume
- 63
- Issue
- 8
- Pages
- 2788-2799
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC4113068
- OpenAlex
- W2129639460
- Cited by
- 73
- References
- 46
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 4 · 2023: 2 · 2022: 3 · 2021: 10 · 2020: 8 · 2019: 9 · 2018: 4 · 2017: 3 · 2016: 7 · 2015: 5 · 2014: 6
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL094722)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- glucagon-like peptide-1, insulin resistance, skeletal muscle microvasculature, muscle blood volume, insulin delivery, glucose disposal, insulin sensitivity, lipid infusion, high-fat diet, hyperinsulinemic-euglycemic clamp, muscle oxygen saturation, incretin-based therapy, glycemic control
- MeSH terms
- Animals, Glucose, Insulin, Insulin Resistance, Lipids, Male, Rats, Sprague-Dawley, Muscle, Skeletal, Neovascularization, Physiologic, Rats, Glucagon-Like Peptide 1, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.